CA2450777C - Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia - Google Patents

Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia Download PDF

Info

Publication number
CA2450777C
CA2450777C CA2450777A CA2450777A CA2450777C CA 2450777 C CA2450777 C CA 2450777C CA 2450777 A CA2450777 A CA 2450777A CA 2450777 A CA2450777 A CA 2450777A CA 2450777 C CA2450777 C CA 2450777C
Authority
CA
Canada
Prior art keywords
compound
leukaemia
tyrosine kinase
kinase activity
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2450777A
Other languages
English (en)
French (fr)
Other versions
CA2450777A1 (en
Inventor
Nicholas J. Donato
Doriano Fabbro
Paul William Manley
Juergen Mestan
Markus Warmuth
Michael Hallek
Moshe Talpaz
Ji Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
GSF - NATIONAL RESEARCH INSTITUTE FOR ENVIRONMENT AND HEALTH
University of Texas System
Original Assignee
Novartis AG
GSF - NATIONAL RESEARCH INSTITUTE FOR ENVIRONMENT AND HEALTH
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, GSF - NATIONAL RESEARCH INSTITUTE FOR ENVIRONMENT AND HEALTH, University of Texas System filed Critical Novartis AG
Priority to CA2810339A priority Critical patent/CA2810339A1/en
Publication of CA2450777A1 publication Critical patent/CA2450777A1/en
Application granted granted Critical
Publication of CA2450777C publication Critical patent/CA2450777C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2450777A 2001-08-10 2002-08-09 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia Expired - Fee Related CA2450777C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2810339A CA2810339A1 (en) 2001-08-10 2002-08-09 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31169001P 2001-08-10 2001-08-10
US60/311,690 2001-08-10
PCT/EP2002/008941 WO2003013540A1 (en) 2001-08-10 2002-08-09 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2810339A Division CA2810339A1 (en) 2001-08-10 2002-08-09 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia

Publications (2)

Publication Number Publication Date
CA2450777A1 CA2450777A1 (en) 2003-02-20
CA2450777C true CA2450777C (en) 2013-04-09

Family

ID=23208019

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2450777A Expired - Fee Related CA2450777C (en) 2001-08-10 2002-08-09 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
CA2810339A Abandoned CA2810339A1 (en) 2001-08-10 2002-08-09 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2810339A Abandoned CA2810339A1 (en) 2001-08-10 2002-08-09 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia

Country Status (6)

Country Link
US (5) US20040248906A1 (cg-RX-API-DMAC7.html)
EP (2) EP1418917A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005502643A (cg-RX-API-DMAC7.html)
CN (1) CN1523991A (cg-RX-API-DMAC7.html)
CA (2) CA2450777C (cg-RX-API-DMAC7.html)
WO (1) WO2003013540A1 (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
WO2003047523A2 (en) * 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
US7276519B2 (en) 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
US20050009891A1 (en) 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
US20050267182A1 (en) 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
WO2005063720A1 (ja) * 2003-12-25 2005-07-14 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
CN1918158B (zh) * 2004-02-14 2011-03-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CA2584493A1 (en) 2004-06-18 2006-01-05 Gpc Biotech, Inc. Kinase inhibitors for treating cancers
CN101106983A (zh) * 2004-11-24 2008-01-16 诺瓦提斯公司 JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合
US20090099197A1 (en) * 2005-11-15 2009-04-16 Bristol-Myers Squibb Company Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof
US20090306094A1 (en) * 2006-03-17 2009-12-10 Bristol-Myers Squibb Company Methods Of Identifying And Treating Individuals Exhibiting Mutant Bcr/Abl Kinase Polypeptides
AU2007235976A1 (en) * 2006-04-07 2007-10-18 Novartis Ag Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
NZ601278A (en) 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
EP2117544A4 (en) * 2006-12-19 2010-03-03 Univ Texas BIOMARKER FOR IDENTIFYING REACTIVATION FROM STAT3 TO SRC INHIBITION
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
CN103319488A (zh) * 2007-03-28 2013-09-25 环状药物公司 布鲁顿氏酪氨酸激酶抑制剂
CN101917999A (zh) * 2007-11-07 2010-12-15 弗尔德里克斯制药股份有限公司 蛋白质运输的调节
MX2011000661A (es) 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
EP2575818A4 (en) 2010-06-03 2013-11-06 Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE INHIBITORS (BTK)
CN103857396A (zh) 2011-07-13 2014-06-11 药品循环公司 布鲁顿酪氨酸激酶抑制剂
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
IN2012CH01573A (cg-RX-API-DMAC7.html) * 2012-04-20 2015-07-10 Advinus Therapeutics Ltd
HK1208460A1 (en) * 2012-05-31 2016-03-04 Gb005, Inc. Protein kinase inhibitors
CA2875986C (en) 2012-06-04 2020-06-09 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
JP6575950B2 (ja) 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
KR20150084923A (ko) 2012-11-15 2015-07-22 파마시클릭스, 인코포레이티드 키나제 억제제로서의 피롤로피리미딘 화합물
US10144828B2 (en) 2012-11-21 2018-12-04 Stratasys, Inc. Semi-crystalline build materials
US9421208B2 (en) 2013-08-02 2016-08-23 Pharmacyclics Llc Methods for the treatment of solid tumors
CA2920534A1 (en) 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
MA38961A1 (fr) 2013-09-30 2018-05-31 Pharmacyclics Llc Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
EP3174539A4 (en) 2014-08-01 2017-12-13 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase
WO2016022942A1 (en) 2014-08-07 2016-02-11 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
CA3083231A1 (en) 2017-11-29 2019-06-06 Adaptive Phage Therapeutics, Inc. Methods of vaccination using icosahedral phage
HRP20250480T1 (hr) 2018-09-10 2025-06-20 Mirati Therapeutics, Inc Kombinacija dasatiniba i adagrasiba za primjenu u liječenju nesitnostaničnog raka pluća
JP7704740B2 (ja) 2019-09-16 2025-07-08 アムジエン・インコーポレーテツド 薬物送達デバイスの外部滅菌の方法
AR122159A1 (es) 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
WO2021252450A1 (en) 2020-06-08 2021-12-16 Adaptive Phage Therapeutics, Inc. Phage display vaccine for covid-19 using a novel peptide sequence
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
JP4145955B2 (ja) 1994-09-29 2008-09-03 ノバルティス アクチェンゲゼルシャフト ピロロ〔２，３−ｄ〕ピリミジン及びその使用
GB9516842D0 (en) 1995-08-17 1995-10-18 Ciba Geigy Ag Various acylated oligopeptides
GB9517060D0 (en) 1995-08-17 1995-10-25 Ciba Geigy Ag Acylated oligopeptide derivatives
US7091346B1 (en) * 1995-11-01 2006-08-15 Novartis Ag Purine derivatives and processes for their preparation
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
AU1794697A (en) 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6100254A (en) * 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
ES2391550T3 (es) 1999-04-15 2012-11-27 Bristol-Myers Squibb Company Inhibidores cíclicos de la proteína tirosina quinasa
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US20050215795A1 (en) 2004-02-06 2005-09-29 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TWI338004B (en) 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors

Also Published As

Publication number Publication date
US20070149539A1 (en) 2007-06-28
JP2005502643A (ja) 2005-01-27
US20060074094A1 (en) 2006-04-06
US8268837B2 (en) 2012-09-18
EP2258371A1 (en) 2010-12-08
CA2810339A1 (en) 2003-02-20
EP1418917A1 (en) 2004-05-19
WO2003013540A1 (en) 2003-02-20
CN1523991A (zh) 2004-08-25
US20090227608A1 (en) 2009-09-10
CA2450777A1 (en) 2003-02-20
US20040248906A1 (en) 2004-12-09
US20070027167A1 (en) 2007-02-01
US8119649B2 (en) 2012-02-21

Similar Documents

Publication Publication Date Title
CA2450777C (en) Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
CA2644841C (en) Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
TW201609100A (zh) 醫藥組合
US20110082101A1 (en) Combinations comprising epothilones and anti-metabolites
JP2013127001A (ja) ピリミジルアミノベンズアミド化合物であるタンパク質キナーゼ阻害剤および１７−ａａｇのようなｈｓｐ９０阻害剤を含む組合せ剤
JP4854198B2 (ja) 慢性リンパ性白血病の処置のためのナイトロジェンマスタードアナログとイマチニブの組み合わせ剤
JP4429732B2 (ja) 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
HK1146804A (en) Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
AU2011202950B2 (en) Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
AU2007200677B2 (en) Combinations comprising epothilones and anti-metabolites
AU2013201915A1 (en) Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
ZA200405099B (en) Combinations comprising epothilones and antimetabolites

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150810